Historical biib News Stories

Biogen's Diranersen Shows Promise in Alzheimer's Treatment, Stock Reacts

Biogen's diranersen shows promise in Alzheimer's treatment, stock reacts.

Biogen's Strategic Moves and Analyst Reactions Shape Stock Performance

Biogen's recent acquisitions and FDA designations influence stock trends.

Biogen's Stock Decline Amidst Recent Developments in Alzheimer's Treatment

Biogen's stock dips following mixed results in Alzheimer's drug trials.

Biogen Surges After EU Spinraza Nod, Insider Gains

Biogen (BIIB) saw share strength after the EU approved a high-dose Spinraza formulation and investor attention rose following a disclosed congressional stock purchase that has since appreciated substantially. These concrete developments improve near-term commercial prospects and have driven sentiment around BIIB.

Biogen Rally: Earnings Beat, Barclays Initiates Q1

Biogen shares recently rose after better-than-expected FY2025 results and upbeat profit metrics, while Barclays started coverage with an Equal-Weight rating. Near-term FDA PDUFA dates for Leqembi (May 24) and SPINRAZA (April 3) and late-stage pipeline readouts make BIIB a catalyst-driven story.

Biogen Beat-and-Raise: Spinraza, Leqembi Catalysts

Biogen’s recent beat-and-raise positions the company for a catalyst-rich H1 2026. Key near-term events — Spinraza PDUFA (Apr 3), Parkinson’s LUMA data (Mar), and a subcutaneous Leqembi decision (May 24) — could materially affect BIIB’s trajectory and investor sentiment.

Biogen Rally: Leqembi FDA Review Boosts BIIB Surge

Biogen (BIIB) surged after a Q4 beat, raised guidance and the FDA accepted a priority filing for a subcutaneous Leqembi formulation with a May 24 PDUFA date. Combined with leadership changes and expanded SPINRAZA approval in Europe, these concrete catalysts are reshaping investor sentiment and could influence liquidity and index relevance.

Biogen Q4 Beat, Leqembi Lift, Nasdaq-100 Exit Now!

Biogen’s recent quarterly beat was driven by strong Leqembi and Tysabri sales, yet the company faces near-term pressure from legacy-product declines and its December removal from the Nasdaq‑100. Guidance and liquidity concerns temper optimism, leaving BIIB’s near-term trajectory dependent on new-product momentum and trading-volume recovery.

Biogen Rallies Before Feb 6 Earnings; Institutions

Biogen (BIIB) jumped on Feb 4 after a short slide, with volume above its 50‑day average as investors positioned ahead of the company’s Feb 6 Q4 2025 earnings. Analysts expect $1.72 EPS and ~$2.21B revenue. Recent institutional increases from Federated Hermes and South Korea’s National Pension Service suggest renewed confidence, but short‑term volatility hinges on guidance and commentary about Biogen’s growth drivers.

Biogen Out of Nasdaq-100: What Investors Must Know

Biogen’s recent removal from the Nasdaq‑100, combined with volatile January trading and an upcoming Feb. 6 earnings report, creates near-term catalysts and headwinds for BIIB. This article explains the index impact, trading implications, and what to watch next.

Biogen Gains: EU Spinraza Approval; Feb 6 Earnings

Biogen (BIIB) earned European approval for a high-dose Spinraza regimen on Jan 12, 2026—an outcome that could strengthen its SMA franchise in Europe. With quarterly results due Feb 6 and recent volatile share moves, investors are watching revenue cadence, guidance, and uptake of the new dosing to judge near-term upside.

Biogen Stock Slides After JP Morgan Week Outflows.

Biogen (BIIB) saw modest share weakness amid broad biotech fund outflows following the J.P. Morgan Healthcare Conference. With analysts largely neutral, lower passive demand after Nasdaq‑100 exclusion, and fresh Alzheimer’s competition highlighted by Novartis’s $1.7B SciNeuro deal, near‑term upside appears limited absent a clear pipeline or corporate catalyst.

Biogen Rally: CHMP OKs High‑Dose Nusinersen Surge!

Biogen stock jumped to a 52-week high after the EMA's CHMP issued a positive opinion for a high-dose nusinersen regimen. The regulatory catalyst, combined with strong trading days in early January, has driven measurable investor interest and could expand Spinraza’s EU positioning pending the European Commission decision.

Biogen: CHMP Nod for Nusinersen; LEQEMBI Wins Data

Biogen received a positive CHMP opinion for a high-dose nusinersen regimen and reported CTAD data strengthening LEQEMBI’s pharmacodynamic profile. Both developments offer near-term regulatory and scientific catalysts for BIIB shares, though analyst coverage and upside remain modest.

Biogen Dropped from Nasdaq-100; HSBC Downgrade Now

Biogen was removed from the Nasdaq‑100 and received an HSBC downgrade last week, triggering index-driven selling, reduced liquidity, and renewed analyst scrutiny. This article explains the immediate market mechanics, investor implications, and key items to watch next for BIIB.

Biogen Removed From Nasdaq-100; ETF Selloff Looms

Biogen (BIIB) will be dropped from the Nasdaq‑100 before trading on Dec. 22, 2025, triggering likely passive selling by index-tracking funds. Recent volume spikes and price weakness contrast with improved technical momentum and a reduced competitive overhang after a rival Alzheimer’s candidate failed Phase 3.

Biogen Slides: 3-Day Drop, Alzheimer Lead Grows Up

Biogen (BIIB) slipped for a third straight day amid light volume even as competitor setbacks in Alzheimer’s research reinforced Biogen’s Leqembi positioning. Recent coverage shows a near-term pullback in the shares, limited reaction across biotech to a Fed rate cut, and concrete competitive developments — all tangible drivers for BIIB investors to evaluate.

Biogen Surges After Dayra Deal, Leqembi sBLA Push.

Biogen (BIIB) climbed after a research collaboration with Dayra Therapeutics and a rolling sBLA submission for Leqembi IQLIK. These concrete developments—$50M upfront, subcutaneous dosing pathway, and recent stock moves—offer clear near-term catalysts.

Biogen Rally: Dayra Pact, Leqembi, Q3 Beat, NovoRx

Biogen (BIIB) climbed after a strategic Dayra Therapeutics collaboration, a rival Alzheimer’s setback from Novo Nordisk, and a stronger-than-expected Q3. Upcoming CTAD presentations and real-world Leqembi data offer additional near-term catalysts.